ABOUT THIS EPISODE
Dr Noriyuki Kasahara speaks with ecancertv at AACR2016 about his cancer-targeting retroviral therapies which illicit host immune responses.
Historically, oncolytic viruses have struggled to compete with host immunity to reach their target and the immunosuppresive tumour environment. But by using a retroviral factor, Dr Kasahara's lab reports selective targeting of cancer cells with a gene primer that in turn responds to a non-toxic pro-drug to kill the 'infected' tumour cells.
Dr Kasahara reports significant extension to patient survival compared to current chemotherapy treatments, with no systemic toxicity and high-tumour specificity.
Trials are ongoing.
Historically, oncolytic viruses have struggled to compete with host immunity to reach their target and the immunosuppresive tumour environment. But by using a retroviral factor, Dr Kasahara's lab reports selective targeting of cancer cells with a gene primer that in turn responds to a non-toxic pro-drug to kill the 'infected' tumour cells.
Dr Kasahara reports significant extension to patient survival compared to current chemotherapy treatments, with no systemic toxicity and high-tumour specificity.
Trials are ongoing.
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
OTHER EPISODES IN THIS PODCAST
Dr Robert Gillies talks to ecancertv at AACR 2016 about novel imaging techniques in tumour habitats.
Considering the stalling durable response rate of many targeted-therapy patients due to tumour evolution, Dr Gillies discusses the value of multiple imaging techniques to determining tumour habitat…
Dr Rafaella Sordella speaks with ecancertv at AACR 2016 about cell plasticity affecting its susceptibility to therapies.
With specific regard to non-genetic mechanisms of resistance in cancer cells, Dr Sordella explains the flexible cell state, how some cells persist and respond to therapies, and …
Dr Philip Low speaks with ecancertv at AACR 2016 about a novel technique to selectively identify tumour cells in vivo.
With potentially toxic side effects to uncontrolled tumour lysis and hard-to-target heterogeneity, Dr Low describes a new method of using fluorescein dye to bridge tumours and T C…
Dr Xose Puente speaks with ecancertv at AACR2016 about his discoveries of mutations in non-coding regions driving tumourigensis in chronic lymphocytic leukaemia.
Using a library of genomic data from CLL patients, Dr Puente's lab were able to determine point mutations outside of the coding regions …
Dr Martine Piccart presents at AACR 2016 about the results of the MINDACT trial.
Using a new diagnostic assay, Mammaprint, to scan for a 70 gene signature, Dr Piccart reports significant predictive potential for determining breast cancer relapse risk.
Disclaimer: The podcast and artwork embedded on this page are from ecancer.org, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
